pylori

HPi1 is a selective and orally active antimicrobial against Helicobacter pylori (IC50: 0.24 μM and a MIC of 0.08-0.16 μg/mL). HPi1 is inactive against other Xaliproden, including the gut commensals, Lactobacillus reuteri, Lactobacillus casei, and Bifidoba

Pyloricidin A is an antibiotic effective against Helicobacter pylori, produced by Bacillus sp. HC-70. It exhibits strong anti-Helicobacter pylori activity and shows no efficacy against other bacteria or yeasts.

Pyloricidin B is an antibiotic specifically effective against Helicobacter pylori, showing potent anti-Helicobacter pylori activity. It exhibits no activity against other bacteria or yeast.

Pyloricidin A2 is an antibiotic effective against Helicobacter pylori, produced by Bacillus species HC-70. It exhibits strong anti-Helicobacter pylori activity but shows no activity against other bacteria and yeast.

Pyloricidin D is an antibiotic effective against Helicobacter pylori.

Pyloricidin C is an antibiotic that targets Helicobacter pylori.

Pyloricidin A1 is an antibiotic effective against Helicobacter pylori produced by Bacillus sp. HC-70. It exhibits strong anti-Helicobacter pylori activity and shows no activity against other bacteria and yeast.

CV-6209 is a potent antagonist of the platelet-activating factor (PAF) receptor.

Rebamipide (OPC12759) is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.

Rabeprazole Sulfide (Rabeprazole Related Compound E) is an antiulcer drug in the class of proton pump inhibitors.

1. Octyl Gallate is an antioxidant approved by the US Food and Drug Administration (FDA) as a food additive. 2. Octyl Gallate has antimetastatic activity. 3. Octyl Gallate shows antimicrobial activity against H. pylori, with a minimum inhibitory concentration (MIC) value of 125 ug/mL. 4. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.5. Octyl Gallate is a potential anticancer agent, it exhibited decreased MCF-7 & MDA-MB-231 survival and induced apoptosis, with IC50 value of 40 uM. 6. Octyl gallate (Octyl 3,4,5-trihydroxybenzoate) has antiviral activity, it shows an inhibitory effect on the growth of herpes simplex virus type 1 (HSV-1) in HEp-2 or Vero cells. 7. Octyl gallate shows antifungal activity against Saccharomyces cerevisiae ATCC7754 and Zygosaccharomyces bailii ATCC 60483.

pNNP (Nitrophenylphosphate) can be used as a substrate for the PP2C assay. pNNP inhibits β-carbonic anhydrase and α-carbonate dehydrogenase, as well as H. pylori Helicobacter pylori. pNNP is a weakly active, tissue-nonspecific alkaline phosphatase modifier. pNNP has been shown to inhibit β-carbonic anhydrase and α-carbonate dehydrogenase.

L-Glutamic acid monosodium salt monohydrate (MSG monohydrate) is an important food additive with gastrointestinal protective effects. It plays a critical role in nutrient metabolism, energy demand, immune response, oxidative stress, signal transduction, and synaptic transmission. L-Glutamic acid monosodium salt monohydrate can induce oxidative stress, DNA damage, and apoptosis in mouse liver and brain tissues. It can protect against gastrointestinal damage caused by NSAIDs and Helicobacter pylori through multiple mechanisms.

HpFabZ Inhibitor 1 (compound 1) is a selective inhibitor of HpFabZ (H. pylori

Finafloxacin, a fluoroquinolone antimicrobial agent from a new 8-cyano subclass, is most effective in slightly acidic environments (pH 5.0-6.0), a condition where other fluoroquinolones typically reduce in activity. It selectively targets bacterial type II topoisomerases, such as DNA gyrase and DNA topoisomerase IV, making it suitable for treating serious bacterial infections particularly in acidic contexts, including urinary tract infections (UTIs) and Helicobacter pylori infections.

Xinjiachalcone A is a natural product isolated from Glycyrrhiza inflata Batalin. Xinjiachalcone A shows both a low MIC and a strong bactericidal activity against H. pylori(MIC : 12.5 to 50 µM, seventeen H. pylori strains).

FR-145715 is a histamine H2 receptor antagonist characterized by its specific anti-Helicobacter pylori activity. This compound is utilized in the study of gastric lesions.

4-Hexen-3-one inhibits the growth of H. pylori in the ATCC 43526 strain and TDR strain. Additionally, this compound suppresses urease activity.

VPC162134 is an antibacterial agent that inhibits H. pylori, C. jejuni, MRSA, and S. epidermidis with minimum inhibitory concentrations (MIC) of 2.9, 17.5, 93.3, and 93.3 μM, respectively. Additionally, VPC162134 acts as an inhibitor of the enzyme pyruvate ferredoxin oxidoreductase (PFOR).

JAK05 exhibits inhibitory activity against Helicobacter pylori, effectively suppressing strains J63, J196, and J107, with a MIC of 3-5 µg/mL. It shows affinity for binding to H+/K+-ATPase, COX-1/2, TNF-α, and PGE2, and possesses antioxidant and anti-inflammatory properties. In a rat model of ethanol-induced gastric ulcers, JAK05 demonstrates anti-ulcer activity.

BAS-118 is a benzamide derivative exhibiting antibacterial activity. For 100 randomly selected strains of Helicobacter pylori, its MIC50, MIC90, and MIC range were ≤0.003, 0.013, and ≤0.003-0.025 mg/L, respectively. BAS-118 shows potential for research as an anti-H. pylori agent.

Urease-IN-20 (compound XBP2) is an inhibitor of Helicobacter pylori (H. pylori), with an IC50 of 0.14 μM for H. pylori inhibition. It effectively decreases apoptosis in GES-1 cells infected with H. pylori and reduces levels of ROS and γH2AX. Urease-IN-20 also demonstrates significant gastric mucosal protective effects, making it suitable for H. pylori research.

Urease-IN-12 (compound 5e) is a competitive urease inhibitor with an IC50 of 0.35 μM, showing potential in inhibiting gastritis and peptic ulcers caused by Helicobacter pylori.

Antibacterialagent 231 (derivative 8) is an antimicrobial compound effective against multidrug-resistant Helicobacter pylori (H. pylori), with a minimum inhibitory concentration ranging from 0.25 to 0.5 μg/mL. It specifically targets the protein translocase subunit SecA and the outer membrane protein assembly factor BamD to inhibit the transport and assembly of bacterial outer membrane proteins (OMPs). Antibacterialagent 231 is suitable for studying the effects of antibiotic treatment on gut microbiome balance.